Oppositional Defiant Disorder Completed Phase 4 Trials for Oxcarbazepine (DB00776)

Also known as: Conduct Disorder / Disruptive Behavior Disorders / Disruptive behaviour disorder / Disruptive Behavior Disorder / Conduct Disorders / Behavior Disorder, Disruptive / Conduct behavior disorder / Conduct behaviour disorder / Unspecified disturbance of conduct

IndicationStatusPhase
DBCOND0032311 (Oppositional Defiant Disorder)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00154362The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.Treatment